Clinical Trial Update: A Dose Escalating Study to Assess the Safety and Tolerability of GT-001 [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 dose-escalation trial evaluating the safety and tolerability of GT-001 for feeding and eating disorders. No eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Feeding and Eating Disorders

Drugs mentioned

• GT-001

Snippet

Sponsor: Gila Therapeutics, Inc. | Conditions: Feeding and Eating Disorders | Phase 1 | Status: COMPLETED